Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Biopharmaceutical	753.08M	896.44M	1.27B	2.27B	2.89B
Biopharmaceutical Growth	-15.99%	-29.67%	-43.92%	-21.33%	24.74%
Others	122.05M	134.37M	135.77M	63.32M	79.01M
Others Growth	-9.17%	-1.03%	114.42%	-19.86%	65.61%
Total	875.13M	1.03B	1.41B	2.34B	2.97B
Total Growth	-15.10%	-26.92%	-39.63%	-21.29%	25.56%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
China	683.16M	751.77M	1.20B	1.70B	1.96B
China Growth	-9.13%	-37.44%	-29.48%	-12.91%	11.05%
Foreign	191.97M	279.04M	208.74M	632.08M	1.01B
Foreign Growth	-31.20%	33.68%	-66.98%	-37.49%	68.05%
Total	875.13M	1.03B	1.41B	2.34B	2.97B
Total Growth	-15.10%	-26.92%	-39.63%	-21.29%	25.56%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 15, 2026

Data Sources Report a data error